Nzyme, a Spanish non-public fairness fund backed by Kibo Ventures, has introduced its closing closing at €160 million to spend money on Spanish corporations working in extremely fragmented B2B sectors, with a give attention to conventional companies which have sturdy transformation potential by means of the adoption of expertise and sector consolidation.
The fund has attracted help from a various base of traders, together with the dedication of CDTI by means of its SICC Innvierte, in addition to Spanish enterprise households, profitable entrepreneurs who determine with the fund’s technique, banks, and worldwide household workplaces with pursuits in Spain.
Vicente Vázquez, Managing Director at Nzyme, stated: “The profitable closing of this fund, in a difficult atmosphere, confirms traders’ confidence within the Nzyme group, our technique, and the potential of Spanish SMEs to remodel and develop. We’re satisfied that by combining enterprise consolidation with technological innovation, we are able to create sturdy leaders in conventional and fragmented sectors.
“We stay dedicated to producing sustainable worth and contributing to the nation’s financial growth by means of strategic investments and a detailed, hands-on strategy with the businesses.”
Nzyme is the newest enterprise capital fund launched by Kibo Ventures, with the mission to catalyse the transformation of the businesses and industries through which it invests. Kibo Ventures is a VC agency was based in 2012 to empower revolutionary European tech entrepreneurs to sort out important challenges and obtain progress by constructing world corporations.
Nzyme prioritises funding in service and software program corporations inside fragmented industries, characterised by their potential to generate worth by means of sustainability and expertise.
Moreover, Nzyme’s administration group is made up of execs with expertise in non-public fairness, expertise, and enterprise transformation, together with Fernando Díaz Solís, Vicente Vázquez Bouza, José Manuel Gasalla, Juan López Santamaría, and Pablo Campos, supported by the Kibo Ventures community.
Moreover, the fund has Oliver Wyman as a strategic advisor, which permits Nzyme to entry superior sector analyses, channel proprietary alternatives, and facilitate the internationalisation of the businesses in its portfolio.
The fund has already made its first investments, together with a notable entry into healthcare distribution, built-in into Kuma Group, in addition to a number of investments in skilled providers corporations. These transactions are a part of Nzyme’s strategic mission to construct trade leaders by means of consolidation and technological innovation in fragmented sectors.
As well as, the fund has superior plans to combine different corporations that may additional strengthen the expansion of its portfolio.
In April 2025, Nzyme accomplished the divestment of Kuma’s dental division, lower than two years after its acquisition, reaffirming its capacity to create worth by means of lively transformation and progress methods.
The fund explains that they make investments with “a prudent and hands-on strategy, specializing in well-managed corporations with strong buildings, supporting them of their growth processes“. The fund prioritizes shut collaboration with Founders and administration groups to facilitate institutionalisation, generational shift, and internationalisation.
The target is to help corporations which have confirmed their value of their native markets, lots of them situated exterior main city facilities, in scaling up, professionalising, and successfully adopting expertise. On this course of, the fund offers key help in probably the most complicated challenges of enterprise progress: transitioning from buildings of 20–40 staff to organisations of over 150 individuals, with scalable processes, built-in expertise, and worldwide ambition.
Nzyme targets corporations with EBITDA beginning at roughly €1 million or round 20 staff as a place to begin to construct sector platforms. The fund anticipates a portfolio of 8 to 10 platforms, making particular person investments of between €15 and €20 million by means of the acquisition and integration of a number of corporations.
The technique combines inorganic progress with the adoption of superior applied sciences – resembling AI, massive information, machine studying, IoT, edge computing, and cloud – to drive operational effectivity, scalability, and aggressive differentiation.
With an lively strategy, the fund applies the traditional non-public fairness levers – administration succession, institutionalisation, and worldwide growth – integrating expertise as a driver of sustainable progress and worth creation.
